Outcomes of Everolimus Plus Endocrine Therapy Following CDK4/6 Inhibitor Therapy for Metastatic Hormone Receptor- Positive Breast Cancer
Received Date : 04 Nov 2023
Accepted Date : 20 Feb 2024
Available Online : 04 Mar 2024
Doi: 10.37047/jos.2023-100188 - Article's Language: EN - Medline ID: 10.37047/JOS.2023-100188
Journal of Oncological Sciences. 2024;10(1):25-31.
This is an open access article under the CC BY-NC-ND license
Objective: This study investigated the effectiveness and safety of everolimus plus endocrine therapy in patients with hormone receptor- positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) after failed cyclin-dependent kinase 4/6 (CDK4/6) inhibitor therapy in a real-world clinical setting. Material and Methods: This was a single-center retrospective cohort study. Patients with HR+/HER2- MBC who underwent everolimus plus endocrine therapy after prior progression with combination of a CDK4/6 inhibitor and a hormonal therapy were included. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan- Meier method, and parameters associated with PFS were assessed by Cox regression analysis. Results: A total of 44 patients were included. The median PFS was 4.1 months [95% confidence interval (CI), 2.8-5.4] and the median OS was 16 months (95% CI, 8.8-23.2). Liver metastasis [hazard ratio (HR), 2.28; 95% CI, 1.09-4.78; p=0.029] and pleural or peritoneal metastases (HR, 3.23; 95% CI, 1.46-7.14; p=0.004) were associated with poor PFS. Multivariate Cox regression analysis after covariate adjustment for age and histology revealed that liver (HR, 2.21; 95% CI, 1.04- 4.69; p=0.038) and pleural or peritoneal metastases (HR, 3.01; 95% CI, 1.35-6.70; p=0.007) were significantly associated with increased risk of PFS events. Conclusion: Everolimus plus endocrine therapy has a moderate effect on PFS in patients with MBC who had previously received a CDK4/6 inhibitor and hormonal agent combination therapy. The effect is more pronounced in patients without liver or pleural/peritoneal metastases.
  1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. [Crossref]  [PubMed] 
  2. Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055. [Crossref]  [PubMed]  [PMC] 
  3. Taylor C, McGale P, Probert J, et al. Breast cancer mortality in 500 000 women with early invasive breast cancer diagnosed in England, 1993-2015: population based observational cohort study. BMJ. Jun 2023;381:e074684. Erratum in: BMJ. July 2023;382:p1744. [Crossref]  [PubMed]  [PMC] 
  4. Guo F, Kuo YF, Shih YCT, Giordano SH, Berenson AB. Trends in breast cancer mortality by stage at diagnosis among young women in the United States. Cancer. 2018;124(17):3500-3509. [Crossref]  [PubMed]  [PMC] 
  5. Jerzak KJ, Bouganim N, Brezden-Masley C, et al. HR+/HER2- advanced breast cancer treatment in the first-line setting: expert review. Curr Oncol. 2023;30(6):5425-5447. [Crossref]  [PubMed]  [PMC] 
  6. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520-529. [Crossref]  [PubMed]  [PMC] 
  7. Gradishar WJ, Anderson BO, Abraham J, et al. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(4):452-478. [PubMed] 
  8. Piezzo M, Chiodini P, Riemma M, et al. Progression-free survival and overall survival of CDK 4/6 inhibitors plus endocrine therapy in metastatic breast cancer: a systematic review and meta-analysis. Int J Mol Sci. 2020;21(17):6400. [Crossref]  [PubMed]  [PMC] 
  9. Gradishar WJ, Moran MS, Abraham J, et al. NCCN Guidelines® Insights: Breast Cancer, Version 4.2023. J Natl Compr Canc Netw. 2023;21(6):594-608. [PubMed] 
  10. Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30(10):870-884. Erratum in: Adv Ther. 2014;31(9):1008-1009. [Crossref]  [PubMed]  [PMC] 
  11. Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Ann Oncol. 2014;25(12):2357-2362. [Crossref]  [PubMed]  [PMC] 
  12. Mo H, Renna CE, Moore HCF, et al. Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors. Clin Breast Cancer. 2022;22(2):143-148. [Crossref]  [PubMed] 
  13. Cook MM, Al Rabadi L, Kaempf AJ, Saraceni MM, Savin MA, Mitri ZI. Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy. Oncologist. 2021;26(2):101-106. [Crossref]  [PubMed]  [PMC] 
  14. Rozenblit M, Mun S, Soulos P, Adelson K, Pusztai L, Mougalian S. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Res. 2021;23(1):14. [Crossref]  [PubMed]  [PMC] 
  15. Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole (BOLERO-2). identifier: NCT00863655. 2009. [Cited: October 3, 2023]. Available from: [Link] 
  16. Merza R, Alekri R, Alekri S, Alsaleh A, Alnasir F. The prevalence and factors associated with iron deficiency anemia in anemic pregnant women. Bahrain Medical Bulletin. 2014;36(3):172-176. [Crossref] 
  17. Denic S, Showqi S, Klein C, Takala M, Nagelkerke N, Agarwal MM. Prevalence, phenotype and inheritance of benign neutropenia in Arabs. BMC Blood Disord. Mar 2009;9:3. [Crossref]  [PubMed]  [PMC]